TNGX — Tango Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$22.31
-$0.04 (-0.18%)
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ. It is led by Malte Peters M.D., based in 201 Brookline Avenue, Boston, MA, United States, 02215, with about 137 employees. Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Latest reported TNGX revenue for 2025-09-30 was $53.8M. Net income was -$62.8M. Revenue was up 1591.6% from 2025-06-30 to 2025-09-30. TNGX currently screens at market cap $5.36B.
Use this TNGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TNGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TNGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Tango Therapeutics Inc even when a live quote feed is slow.
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
TNGX Key Statistics
Market Cap
$5.36B
Volume
2.28M
Previous Close
$24.51
Day Range
$24.35 – $25.61
P/B Ratio
13.68
EPS
-$1.19
Revenue
$42.07M
Net Income
-$130.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+15.2%
Profit Margin
-309.7%
Employees
137
TNGX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $42.07M | $36.53M | $24.86M | $37.04M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$130.30M | -$101.74M | -$108.18M | -$58.23M |
| EPS (Diluted) | -$1.19 | -$1.08 | -$1.23 | -$0.94 |
Total Assets
$316.49M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$69.53M
Operating Cash Flow
-$131.50M
Free Cash Flow
$0.00
Tango Therapeutics Inc Company Information
- President, CEO & Director
- Malte Peters M.D.
- Headquarters
- 201 Brookline Avenue, Boston, MA, United States, 02215
- Website
- www.tangotx.com
- Phone
- 857 320 4900
- IPO / Founded
- 2020-09-03
- Sector
- Healthcare
- Industry
- Biotechnology